Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.
J Clin OncolJun 26, 2026 (epub)
Clinical ResearchOncology (Medical)
Makoto Tahara, Naomi Kiyota, Takeshi Kodaira et al.
✦ AI-curated · Sources linked
In 30 seconds
The JCOG1008 trial evaluated the long-term outcomes of chemoradiotherapy with weekly versus 3-weekly cisplatin in 261 patients with postoperative high-risk locally advanced squamous cell carcinoma of the head and neck. With a median follow-up of 5.6 years, the 5-year overall survival was 71.2% for weekly cisplatin and 58.7% for 3-weekly cisplatin, confirming the noninferiority of the weekly regimen.
Key findings
- 5-year overall survival was 71.2% for weekly cisplatin versus 58.7% for 3-weekly cisplatin.
- The hazard ratio for overall survival was 0.76 (95% CI, 0.52 to 1.12).
- 5-year relapse-free survival was numerically better in the weekly cisplatin arm.
- No late adverse event showed more than a 10% difference between the two treatment arms.
Why it matters
These findings provide evidence that weekly cisplatin is a viable alternative to 3-weekly cisplatin in postoperative chemoradiotherapy for high-risk head and neck cancer, potentially influencing treatment protocols and patient management strategies.